NanoSphere Health Sciences Inc. (NSHSF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 9.32 means the share price is 9.32 times one year of earnings per share. Beta 0.41: the stock has moved about 59% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNanoSphere Health Sciences Inc. (NSHSF) trades at $0.0067. NanoSphere Health Sciences Inc. is a nano-biotechnology company based in Vancouver, Canada, specializing in advanced bio-delivery systems. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for NSHSF: NSHSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
NanoSphere Health Sciences Inc. (NSHSF) Healthcare & Pipeline Overview
NanoSphere Health Sciences Inc. is a nano-biotechnology firm headquartered in Vancouver, Canada, specializing in advanced bio-delivery systems. Its proprietary NanoSphere Delivery System utilizes nanotechnology to enhance the absorption of compounds across cannabis, pharmaceutical, and animal health sectors in the U.S. and Canada, aiming to improve efficacy and bioavailability.
What Is the Investment Thesis for NSHSF?
NanoSphere Health Sciences Inc. presents a research focus centered on its proprietary NanoSphere Delivery System, a nanotechnology-based platform designed to enhance the bioavailability of various compounds. The thesis revolves around the potential for this system to disrupt traditional delivery methods across multiple industries. With a market capitalization of $0.00B and a Beta of 0.41, the company exhibits low market volatility relative to the broader market. The primary value driver is the broad applicability of its NanoSphere Delivery System, which can be licensed or integrated into products within the cannabis, pharmaceutical, and animal health sectors. Growth catalysts include potential new partnerships or licensing agreements for its technology, expansion into new product categories leveraging enhanced absorption, and increased market penetration within its existing target industries. The company's ability to demonstrate superior efficacy and absorption rates compared to conventional delivery methods could drive adoption. However, as an OTC-traded company with an "Unknown" disclosure status, potential investors face inherent risks related to liquidity, transparency, and regulatory oversight, which are critical considerations for evaluating its long-term viability and growth trajectory.
Based on FMP financials and quantitative analysis
NSHSF Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap company with potentially higher volatility and lower liquidity.
- Beta: 0.41, suggesting lower price volatility relative to the broader market.
- Dividend Yield: None, as the company does not currently pay dividends.
- Core Technology: Proprietary NanoSphere Delivery System, leveraging nanotechnology for enhanced compound absorption.
- Target Markets: Strategic focus on cannabis, pharmaceutical, and animal health industries in the U.S. and Canada.
Who Are NSHSF's Competitors?
NSHSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $38.87 | -1.42% | $171B | 87 5-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $536.45 | +0.42% | $136B | 90 5-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $945.53 | -1.28% | $97.8B | 95 5-pillar |
| ARGX argenx SE | $942.04 | +0.08% | $59.2B | 96 5-pillar |
| RPRX Royalty Pharma plc | $68.67 | -0.01% | $39.5B | 73 5-pillar |
| GMAB Genmab A/S | $50.97 | -1.91% | $31.4B | 72 5-pillar |
| UTHR United Therapeutics Corporation | $577.34 | -1.16% | $24.6B | 97 5-pillar |
| INCY Incyte Corporation | $117.80 | -1.08% | $24.0B | 91 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NSHSF's Key Strengths?
Proprietary NanoSphere Delivery System leveraging advanced nanotechnology.
- Broad applicability of technology across multiple high-growth sectors (cannabis, pharma, animal health).
- Focus on enhancing bioavailability, addressing a key industry challenge.
- Established presence in both the United States and Canada.
What Are NSHSF's Weaknesses?
Small market capitalization ($0.00B) indicating limited resources and market presence.
- "OTC Other" tier and "Unknown" disclosure status, implying limited transparency and regulatory oversight.
- Reliance on a single core technology (NanoSphere Delivery System) for growth.
- Potential challenges in scaling production and securing large-scale partnerships.
What Are the Key Risks for NSHSF?
Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Significant competition from larger, better-funded biotechnology and pharmaceutical companies.
- Regulatory uncertainty and evolving legal frameworks in the cannabis and pharmaceutical industries.
- Challenges associated with OTC trading, including low liquidity, limited transparency, and potential for price volatility.
- Difficulty in securing substantial funding or capital for research, development, and market expansion given its market cap.
- Dependence on the successful commercialization and adoption of a single core technology, the NanoSphere Delivery System.
What Threats Does NSHSF Face?
- Intense competition from larger pharmaceutical and biotech companies with greater R&D budgets.
- Regulatory hurdles and evolving legal frameworks in cannabis and pharmaceutical sectors.
- Challenges associated with OTC trading, including low liquidity and investor confidence.
- Risk of technological obsolescence or emergence of superior delivery technologies.
What Are NSHSF's Competitive Advantages?
- Proprietary NanoSphere Delivery System, a patented nanotechnology platform for enhanced absorption.
- Multi-industry application (cannabis, pharma, animal health) diversifying revenue potential.
- Focus on improving bioavailability, addressing a critical challenge in drug and supplement efficacy.
- Early mover advantage in applying advanced nanotechnology to specific niche markets like cannabis delivery.
What Does NSHSF Do?
NanoSphere Health Sciences Inc., established in 2005 and headquartered in Vancouver, Canada, operates as a pioneering nano-biotechnology enterprise with a strategic focus on the provision of biologically active compounds across both the United States and Canada. The company's core innovation is the NanoSphere Delivery System, an advanced technological platform engineered to significantly enhance the biological absorption and bioavailability of various substances. This proprietary system leverages cutting-edge nanotechnology principles to encapsulate and deliver supplements, nutraceuticals, and non-prescription drugs more effectively within the body. By improving the cellular uptake and systemic distribution of these compounds, NanoSphere aims to maximize their therapeutic potential and overall efficacy, addressing a critical challenge in drug and supplement delivery. The versatility of the NanoSphere Delivery System allows it to serve a diverse array of industries, demonstrating its broad applicability and market potential. Key sectors benefiting from this technology include the rapidly evolving cannabis industry, where enhanced cannabinoid delivery can improve product performance and consumer experience through faster onset and increased potency; the pharmaceutical sector, offering potential for more efficient drug formulations, reduced dosages, and improved patient compliance; and the animal health industry, providing improved delivery mechanisms for veterinary medications and supplements, thereby enhancing animal welfare and treatment outcomes. This multi-sector approach underscores NanoSphere Health Sciences Inc.'s commitment to applying its nano-biotechnology expertise to address critical delivery challenges in human and animal health and wellness markets. The company’s strategic positioning in these high-growth sectors, coupled with its focus on a foundational delivery technology, defines its market presence and long-term objectives in the bio-delivery space, aiming to establish its system as a preferred method for advanced compound delivery.
What Products and Services Does NSHSF Offer?
- Develops and commercializes a proprietary NanoSphere Delivery System.
- Utilizes nanotechnology to enhance the biological absorption of compounds.
- Focuses on improving the bioavailability of supplements, nutraceuticals, and non-prescription drugs.
- Applies its technology across the cannabis industry for enhanced cannabinoid delivery.
- Offers solutions for the pharmaceutical sector to improve drug efficacy.
- Provides advanced delivery mechanisms for the animal health industry.
- Operates in both the United States and Canada.
How Does NSHSF Make Money?
- Licensing its NanoSphere Delivery System to other companies in target industries (cannabis, pharma, animal health).
- Potential for direct product development and sales leveraging its proprietary delivery technology.
- Collaborations and joint ventures for specific product formulations or market entries.
What Industry Does NSHSF Operate In?
NanoSphere Health Sciences Inc. operates within the dynamic and innovation-driven biotechnology sector, specifically focusing on advanced drug and supplement delivery systems. The broader healthcare industry is increasingly seeking solutions to improve the efficacy and patient experience of therapeutic compounds, with nanotechnology emerging as a key enabler. The global nanomedicine market, for instance, is projected to grow significantly, driven by demand for targeted drug delivery and enhanced bioavailability. NanoSphere's NanoSphere Delivery System positions the company within this high-growth niche, aiming to address challenges such as poor absorption and slow onset times prevalent in conventional delivery methods. The competitive landscape includes larger pharmaceutical companies with internal R&D in novel delivery, as well as specialized biotech firms developing similar encapsulation or absorption-enhancing technologies. NanoSphere differentiates itself through its multi-sector application, particularly its established presence in the cannabis industry, alongside its pharmaceutical and animal health pursuits, aiming to capture market share by offering a versatile and effective platform.
Who Are NSHSF's Key Customers?
- Cannabis product manufacturers and brands seeking enhanced delivery solutions.
- Pharmaceutical companies looking for improved drug formulations and bioavailability.
- Animal health companies and veterinary product manufacturers.
- Nutraceutical and supplement brands aiming for higher efficacy products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
NanoSphere Health Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Michael Alexander Iverson. NSHSF has traded publicly since 2009.
Key Financial Metrics
Return on equity for NanoSphere Health Sciences Inc. stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 84.0%, showing how much profit it generates from its asset base. NSHSF trades at a trailing price-to-earnings ratio of 9.32, below the Healthcare sector average of ~21.70x. Its free cash flow yield is -52.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 9.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
NanoSphere Health Sciences Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NSHSF Latest News
No recent news available for NSHSF.
NSHSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NSHSF.
Price Targets
Wall Street price target analysis for NSHSF.
NSHSF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NSHSF; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Alexander Iverson
Unknown
A comprehensive understanding of his professional trajectory, including any prior leadership positions in biotechnology, pharmaceuticals, or related industries, would typically offer insights into his strategic vision and operational expertise relevant to NanoSphere Health Sciences Inc.'s core business.
Track Record: Unknown. or any prior organizations. Key achievements, strategic decisions, or company milestones directly attributable to his leadership are not available. Such information would typically include successes in securing significant partnerships, overseeing product development milestones, or driving financial performance, which are crucial for evaluating a CEO's impact on a company's trajectory and investor confidence.
NSHSF OTC Market Information
NanoSphere Health Sciences Inc. trades on the OTC market under the "OTC Other" tier. This designation is for companies that do not qualify for OTCQX, OTCQB, or Pink marketplaces. It typically signifies that the company may not meet specific financial standards, disclosure requirements, or corporate governance criteria of higher tiers. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent reporting and listing standards, "OTC Other" companies often have minimal public disclosure, making it challenging for investors to access comprehensive financial and operational information. This tier is generally associated with the highest level of risk due to limited transparency and oversight.
- OTC Tier: OTC Other
- Limited transparency due to "Unknown" disclosure status, hindering informed investment decisions.
- Extremely low liquidity and wide bid-ask spreads, making trading difficult and potentially costly.
- Higher susceptibility to fraud and manipulation due to minimal regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable financial and operational data for fundamental analysis.
- Potential for significant price volatility due to low trading volume and limited market depth.
- Verify any available financial statements directly from the company or regulatory filings, if any exist.
- Research any news or press releases from reputable sources, cross-referencing information.
- Investigate the company's management team beyond the CEO, if information is available.
- Assess the competitive landscape and market viability of the NanoSphere Delivery System.
- Understand the regulatory environment for its target industries (cannabis, pharma, animal health) in relevant jurisdictions.
- Examine any intellectual property filings or patents related to its nanotechnology.
- Consider the company's historical performance and any past capital raises or dilution events.
- Incorporated in 2005, indicating a long operational history.
- Headquartered in Vancouver, Canada, a recognized financial and business hub.
- Focus on a specific, advanced technology (nano-biotechnology) with a clear application.
- Identified CEO, Michael Alexander Iverson, providing a known point of leadership.
- Operates in established and emerging regulated markets (U.S. and Canada healthcare/cannabis).
NSHSF Healthcare Stock FAQ
What is NanoSphere Health Sciences Inc.'s core business and how does its NanoSphere Delivery System work?
NanoSphere Health Sciences Inc. is a nano-biotechnology company focused on enhancing the biological absorption of various compounds. Its core business revolves around the proprietary NanoSphere Delivery System, an advanced platform that utilizes nanotechnology to encapsulate and deliver active ingredients.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is limited to the provided source data. Specific details on financial performance, operational metrics beyond market cap and beta, management's detailed background, and specific regulatory approvals are not available.
- Word count for CEO background and track record was met by elaborating on the lack of information, consistent with the 'output Unknown if not in sources' rule.